Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB2 | P30411 | 3/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8569946 | 0.93 | BDKRB2 (0.71) | BDKRB2 | |
| SCHEMBL8560380 | 0.90 | BDKRB2 (0.69) | BDKRB2 | |
| SCHEMBL8560851 | 0.88 | BDKRB2 (0.81) | BDKRB2 | |
| Hydrochloric Acid SCHEMBL8566083 | 0.87 | BDKRB2 (0.81) | BDKRB2 | |
| SCHEMBL8565770 | 0.85 | BDKRB2 (0.68) | BDKRB2 | |
| SCHEMBL8569086 | 0.84 | BDKRB2 (0.84) | BDKRB2 | |
| SCHEMBL8569532 | 0.84 | BDKRB2 (0.81) | BDKRB2 | |
| Hydrochloric Acid SCHEMBL8567692 | 0.84 | BDKRB2 (0.84) | BDKRB2 | |
| Hydrochloric Acid SCHEMBL8567105 | 0.83 | BDKRB2 (0.81) | BDKRB2 | |
| SCHEMBL8565609 | 0.83 | BDKRB2 (0.71) | BDKRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0596406-B1 | Imidazo (1,2-a) Pyridines as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO (JP) | 1998-12-16 | — | — | EP | disclosed |
| US-5574042-A | ANTAGONIST FOR BRADYKININS AS ANTIALLERGENS, AUTOIMMUNE DISEASES, ANTIINFLAMMATORY AGENTS, SHOCK OR PAIN | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 1996-11-12 | — | — | US | disclosed |
| EP-0596406-A1 | Imidazo (1,2-a) Pyridines as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-05-11 | — | — | EP | disclosed |